Biotech News
Related news
AVIRAtea2026-07-14 11:00 EST
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
AVIRAtea2026-06-25 11:00 EST
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
ENTAEnanta Pharmaceuticals2026-06-18 11:00 EST
Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
ENTAEnanta Pharmaceuticals2026-04-13 11:00 EST
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria
ANTXAN2 Therapeutics2026-06-04 11:00 EST
AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease
SCYXSCYNEXIS2026-06-30 12:00 EST
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
ASMBAssembly Biosciences2026-05-13 06:00 EST
Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026
IMNNImunon2026-08-26 12:30 EST
IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001
VIRIVirios Therapeutics2026-07-20 12:30 EST
Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
MBRXMoleculin Biotech, Inc.2026-05-29 12:21 EST
Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits
Atea
Oral Antiviral Therapeutics Atea Pharmaceuticals develops oral antiviral therapies for serious viral diseases. Its pipeline is built around nucleotide and nucleoside analog chemistry and combination treatment strategies. Bemnifosbuvir and Ruzasvir The lead regimen combines the nucleotide polymerase inhibitor bemnifosbuvir with the NS5A...
Recent company news
AVIRAtea2026-09-08 11:00 EST
Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
AVIRAtea2026-08-12 20:05 EST
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
AVIRAtea2026-08-05 11:00 EST
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
AVIRAtea2026-07-28 11:00 EST
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
AVIRAtea2026-07-14 11:00 EST
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
Stock data
- Close
- 5.26 USD
- Market cap
- 341.72M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States